Vera Therapeutics Inc (VERA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.03B
Last updated: Nov 17, 2026 at 11:05 AM ET
Vera Therapeutics Inc (VERA) Stock Forecast
Analysts expect Vera Therapeutics (VERA) to earn -$5.95 per share in the fiscal year ending Dec 31, 2026, on revenue of $31.20M. Of 14 analysts, 12 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.07, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 7.1% |
| Buy | 11 | 78.6% |
| Hold | 2 | 14.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 725.8%.
- Fiscal year ending Dec 31, 2026
- -$5.95
- EPS consensus, revenue $31.20M
- Fiscal year ending Dec 31, 2027
- -$3.92
- EPS consensus, revenue $257.64M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$5.95 | -$6.61 to -$5.65 | 8 | $31.20M | $22.73M to $42.48M | 11 |
| Dec 31, 2027 | -$3.92 | -$5.18 to -$2.89 | 8 | $257.64M | $179.00M to $346.89M | 11 |
Quarterly Estimates
The EPS consensus rises from -$1.40 for the quarter ending Dec 31, 2026 to -$1.24 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.40 | -$2.12 to -$1.17 | 13 | $19.09M | $10.78M to $33.81M | 12 |
| Mar 31, 2027 | -$1.24 | -$1.39 to -$1.06 | 4 | $39.93M | $33.20M to $46.93M | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$6.34.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$5.95 | -$6.27 | -$6.25 | -$6.27 | -$6.34 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.92 | -$4.28 | -$4.25 | -$4.37 | -$4.44 | N/A |
| Quarter ending Mar 31, 2027 | -$1.24 | -$1.33 | -$1.29 | -$1.30 | -$1.33 | N/A |
Frequently Asked Questions About VERA
What is the VERA stock forecast?
Consensus analyst estimates put Vera Therapeutics's EPS at -$5.95 for the fiscal year ending Dec 31, 2026, on revenue of $31.20M. The consensus rating from 14 analysts is Buy.
How do analysts rate VERA stock?
Of 14 analysts covering Vera Therapeutics, 1 rates it Strong Buy, 11 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from VERA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$5.95, with estimates from -$6.61 to -$5.65 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.92, with estimates from -$5.18 to -$2.89 from 8 analysts.
What revenue do analysts expect from Vera Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $31.20M, with estimates from $22.73M to $42.48M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $257.64M, with estimates from $179.00M to $346.89M.
How many analysts cover VERA?
14 analysts rate Vera Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
VERA pages: Overview, Earnings, Forecast, Financials, Competitors